The reduced MATE1 and PMAT expression observed in AD may therefore underpin the heightened sensitivity to amisulpride observed in the clinical population especially as together our in silico and in vitro studies suggested that amisulpride was a substrate for MATE 1 and PMAT. The gene discussed is SLC47A1; the disease is Alzheimer disease.